Navigation Links
Researcher tests drug's impact on neurological disease affecting women
Date:6/7/2011

EAST LANSING, Mich. A rare but increasingly more common disease striking overweight, younger women is the focus of a clinical trial at Michigan State University, where an osteopathic physician is testing the effectiveness of a certain drug against a potentially blindness-causing ailment.

Idiopathic intracranial hypertension, known as IIH or pseudo-tumor cerebri, is a neurological disease resulting in increased pressure around the brain, specifically in the absence of a tumor. Symptoms include severe headaches, nausea and double vision, and if left untreated, IIH can lead to vision loss and blindness.

Eric Eggenberger, professor and associate chairperson in MSU's Department of Neurology and Ophthalmology, is leading a clinical trial to test the ability of a commonly used diuretic known as acetazolamide in reducing or reversing vision loss in patients with IIH. Diuretics are drugs that increase the rate of urination.

"While weight loss is always recommended for women suffering from IIH, many other treatments are used to battle the disease by decreasing pressure around the brain," said Eggenberger, a member of MSU's HealthTeam.

"The problem is, none of these strategies have been verified by clinical trials, and there is no compelling evidence on which treatments work best and why."

In addition, he said, more evidence is needed on the potential side effects of drugs such as acetazolamide.

Though IIH is rather rare, affecting only 22 out of every 100,000 Americans, its incidence rate is rising in parallel with the obesity epidemic sweeping the nation. The cause of the endocrine-based disease is not known, but it usually affects women of child-bearing age who are overweight or obese. It is rare in post-menopausal women and men of all ages.

The clinical trial run by Eggenberger at MSU has three main goals: establish evidence-based treatment strategies to restore and protect vision, follow patients for up to four years to observe long-term treatment outcomes and help determine the cause of IIH.

All patients in the trial will receive Web- and phone-based diet information to help subjects lose weight. The study also will randomly assign patients to one of two groups: those receiving acetazolamide and those receiving a placebo. Patients will be monitored for six months to test the impact of the drug.

Subjects also will undergo genetic screening, specifically looking at vitamin A and genes that may be risk factors for IIH. That analysis could help researchers with the frustrating task of pinpointing what causes the disease, Eggenberger said.


'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert  

Related medicine news :

1. A decade dedicated to breast cancer care advocacy garners ASCO Award for researcher
2. Researchers discover biochemical weakness of malaria parasite -- vaccine to be developed
3. Researchers find that inhibiting microRNAs may help prevent degenerative eye disorders
4. CWRU researcher studies ways to help teens overcome fears and stigmas of mental illness
5. Calorie-burning brown fat is a potential obesity treatment, researchers say
6. City of Hope researchers to present rectal cancer, palliative care, benchmarking studies at ASCO
7. U of Alberta researchers hoping to stop heart disease in cancer patients before it starts
8. U of A researchers hope to stop heart
9. UofL researchers uncover mechanism in saliva production
10. UF researchers suggest cholera vaccination strategies for Zimbabwe
11. Researchers characterize epigenetic fingerprint of 1,628 people
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researcher tests drug's impact on neurological disease affecting women
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
(Date:10/12/2017)... Miramar, FL (PRWEB) , ... October 12, 2017 ... ... is presenting the latest in wound care advancements to physician colleagues, skilled nursing ... lecture is titled, "Navigating the Treacherous Waters of Wound Care." , "At many ...
(Date:10/12/2017)... CHICAGO (PRWEB) , ... October ... ... innovator in life sciences content management, presents its enhanced Pepper Flow promotional ... Oct. 16 -18, 2017. Pepper Flow’s increased insight-driven capabilities help marketers streamline ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") ... Surgical facility in Las Piedras, Puerto Rico ... and blades. ... the facility sustained minor structural damage, temporary loss of ... Repairs have been completed, manufacturing operations have resumed, and ...
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
Breaking Medicine Technology: